🧠 Just published in @thelancetoncol.bsky.social: Updated RANO and EANO recommendations on the clinical use of PET imaging in gliomas. 🔗 Read more: www.thelancet.com/journals/lan... #NeuroOncology #Glioma #PETimaging #EANO #RANO #BrainTumor #LancetOncology

🧠 👉New clinical practice guideline in The Lancet Oncology. Out of the RANO group, we are proud to present our updated multidisciplinary, evidence-based guideline on PET imaging in patients with glioma. www.sciencedirect.com/science/arti... 🔗 #NeuroOncology #PETimaging #Glioma #RANO

Live from #ASCO25 in Chicago: presentation of latest results on HER3-DXd efficacy and safety in patients with leptomeningeal metastatic disease of solid tumors - with simultaneous publication in Nature Medicine. Learn more: doi.org/10.1038/s415... #NeuroOncology

Excellent debates and talks in Vienna during the second day of #NMN2025 meeting. Already looking forward to next year! @nmnsymposium.bsky.social @galldiks.bsky.social @nathaliealbert.bsky.social @marjoleingeurts.bsky.social

🧠New in Nature Medicine (#OpenAccess): This study explores the impact of neoadjuvant triplet immune checkpoint blockade in newly diagnosed #glioblastoma. 🔗Full article: www.nature.com/articles/s41... #EANOessentials #NeuroOncology #Glioma #Immunotherapy

Research focusing on borderline findings in O-(2-[18F]-Fluoroethyl)-l-Tyrosine PET for suspected glioma relapse is now available in Journal of Nuclear Medicine. Learn more 🔗 pubmed.ncbi.nlm.nih.gov/39819686/ #EANOessentials #NeuroOncology #Glioma @snm-mi.bsky.social

🎗️ Today is #WorldCancerDay – a reminder of the ongoing fight against cancer and the need for research, collaboration & innovation in all types, including #NeuroOncology. At #EANO, we’re dedicated to advancing science and patient care. Together, we can make a difference! 💙

New study provides further data on the use of tumor-treating fields in patients with newly diagnosed glioblastoma: academic.oup.com/noa/article/... #NeuroOncology #Glioma #braintumor #glioblastoma

Happy to share our latest on the value of multidisciplinary neuro-oncological tumor boards to increase the accuracy of FET PET for identifying brain tumor relapse. #AminAcidPet #Glioma #btsm #BrainMet t.co/C39Lcs01ki

Just released: Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0 👉 link.springer.com/article/10.1... #EANOessentials #NeuroOncology #BrainMetastases #PET #btsm

This study, published in this month’s Journal of Nuclear Medicine, examines whether intraarterial PRRT or intravenous PRRT is more effective in treating these recurring tumors. Are you surprised by the results? jnm.snmjournals.org/content/65/1...

🚨New research alert! The results are in from the first long-term study of intraarterial peptide receptor radionuclide therapy in treating advanced meningioma. Read the article here: jnm.snmjournals.org/content/65/1...

We’re launching #EANOessentials! 🚀 From now on, this hashtag will highlight selected publications from all areas of neuro-oncology – Stay tuned! ✨ #NeuroOncology #CancerResearch #btsm #EANO

Great fun to write this perspective with @lukasbunse.bsky.social @platten-lab.bsky.social @dkfz-iic.bsky.social @dkfz.bsky.social on a highly interesting study by the Bardeesy Lab. This study provides additional mechanistic rationale to combine IDH inhibitors with T cell activating therapies.

Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lesoons ignored? academic.oup.com/neuro-oncolo...

🚨 Study by Galldiks et al. showing metabolic response to vorasidenib in IDH-mut gliomas using PET monitoring. This highlights FET PET’s potential to provide earlier & more informative assessments of treatment response than MRI in patients receiving IDH-inhibitors academic.oup.com/noa/advance-...